WuXi begins construction on $150m disposable biomanufacturing site in China

By Zachary Brennan contact

- Last updated on GMT

WuXi begins construction on $150m disposable biomanufacturing site in China

Related tags: Biotechnology, Manufacturing, Cell culture, Wuxi

WuXi PharmaTech subsidiary WuXi Biologics has begun construction on a new $150m biologics manufacturing facility in Wuxi, China, which is expected to be the largest mammalian cell culture manufacturing sire using disposable bioreactors in the world.

To be completed by January 2017, the new facility will also be the largest biologics manufacturing facility in China. This added capacity will support WuXi's biologics manufacturing pipeline in the near term.

The new facility will house fourteen 2000L disposable bioreactors for fed-batch cell culture and two 1000L bioreactors for perfusion runs. The facility will also be built to run advanced continuous or semi-continuous manufacturing processes in addition to traditional fed-batch and perfusion modes. 

This facility further expands WuXi's biologics manufacturing capabilities, which also includes biologics clinical drug substance and drug product manufacturing facilities in Wuxi city, which meet cGMP standards of the US, EU and China.

 Ge Li, Chairman and CEO of WuXi PharmaTech, who recently put forth a bid to take the contract developer and manufacturer private​, noted: "This project continues to strengthen WuXi's capabilities in integrated biologics discovery, development, and manufacturing services. We maintain the highest quality standards to expedite global development of biologics for both international clients and Chinese companies​."

Related news

Show more

Related products

show more

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Why Blister Packaging: Things to Consider

Why Blister Packaging: Things to Consider

Catalent Pharma Solutions | 03-Dec-2020 | Insight Guide

The decision to use blister packaging for either clinical trials or commercial drug manufacturing comes with a host of factors to consider. Pharmaceutical...

Innovations in OSD

Innovations in OSD

Recorded the 06-Oct-2020 | Webinar

This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

Related suppliers

Follow us

Products

View more

Webinars